Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/19/2023 | $5.00 | Strong Buy | Raymond James |
| 10/13/2022 | $5.00 | Buy | Mizuho |
| 11/11/2021 | $5.00 | Outperform → Strong Buy | Raymond James |
| 11/9/2021 | $4.50 | Overweight | Cantor Fitzgerald |
| 10/26/2021 | $6.00 → $5.00 | Outperform | Raymond James |
| 8/12/2021 | $7.00 → $6.00 | Buy | HC Wainwright & Co. |
| 7/6/2021 | $10.00 → $7.00 | Buy | HC Wainwright & Co. |
8-K - ADMA BIOLOGICS, INC. (0001368514) (Filer)
10-Q - ADMA BIOLOGICS, INC. (0001368514) (Filer)
8-K - ADMA BIOLOGICS, INC. (0001368514) (Filer)
On CNBC's “Mad Money Lightning Round,” Jim Cramer said Salesforce, Inc. (NYSE:CRM) has been a huge winner and recommended holding the stock. “It does have trouble getting traction,” he added. Salesforce reportedly cut around 300 roles to streamline operations, highlighting the tech industry's ongoing focus on cost control. ADMA Biologics, Inc. (NASDAQ:ADMA) has been a rocket, Cramer said. “If I were you, I would take some off the table.” On May 9, ADMA Biologics reported better-than-expected first-quarter financial results and issued strong FY24 and FY25 revenue guidance. When asked about Ouster, Inc. (NYSE:OUST), he said, “I would actually take some off the table. It's another p
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 50 points on Thursday. Shares of Leslie’s, Inc. (NASDAQ:LESL) fell sharply in today's pre-market trading after the company issued preliminary third-quarter financial results below estimates and cut its FY24 guidance. After the market close on Wednesday, Leslie's announced it now expects third-quarter revenue of approximately $570 million versus estimates of $615.407 million. The pool supply company anticipates third-quarter adjusted earnings of 32 cents to 33 cents per share versus Benzinga Pro estimates of 42 cents per share. Leslie's also cut its full-year 2024 revenue guidance from a range of $1.14
ADMA Biologics's (NYSE:ADMA) short percent of float has fallen 23.1% since its last report. The company recently reported that it has 7.27 million shares sold short, which is 3.23% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.87 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interes
3Q 2024 Total Revenue of $119.8 Million, a 78% Increase Y-o-Y 3Q 2024 GAAP Net Income of $35.9 Million, a 1,300% Increase Y-o-Y 3Q 2024 Adjusted EBITDA(1) of $45.4 Million, a 256% Increase Y-o-Y KPMG LLP Engaged as New Independent Registered Public Accounting Firm FY 2024 and 2025 Total Revenue Guidance Increased to More Than $415 Million and $465 Million, Respectively FY 2024 and 2025 GAAP Net Income Guidance Increased to More Than $120 Million and $165 Million, Respectively FY 2024 and 2025 Adjusted EBITDA Guidance Increased to More than $160 Million and $215 Million, Respectively Conference Call Scheduled for Today at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON,
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 29, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report third quarter 2024 financial results on November 7, 2024, after the U.S. financial markets close. ADMA's management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates. To access the conference call, please dial (888) 596-4144 and refer to conference ID 2959956. It is recommended that you join approximately 10
2Q 2024 Total Revenue of $107.2 Million, a 78% Increase Y-o-Y 2Q 2024 GAAP Net Income of $32.1 Million, a $38.4 Million Increase Y-o-Y 2Q 2024 Adjusted EBITDA(1) of $44.5 Million, a Nearly 600% Increase Y-o-Y Commercial Scale Production of ADMA's Innovative Biologics Manufacturing Process Supports a Potential Yield Enhancement of Approximately 20% from Same Starting Plasma FY 2024 and 2025 Total Revenue Guidance Increased to More Than $400 Million and $445 Million, Respectively FY 2024 GAAP Net Income Guidance Increased to More Than $105 Million and Adjusted EBITDA Guidance Increased to More Than $150 Million FY 2025 GAAP Net Income Guidance Increased to More than $155 Million and
RAMSEY, N.J. and BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced it will join the S&P SmallCap 600 index, effective prior to the open of trading on Monday, September 23, 2024. The S&P SmallCap 600 seeks to measure the small-cap segment of the U.S. equity market. "ADMA's inclusion in the S&P SmallCap 600 index is a significant milestone for our company," Adam Grossman, President and Chief Executive Officer of ADMA. "We expect this inclusion will increase our visibility within the investment communit
NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 18, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the appointment of Young T. Kwon, Ph.D., to its Board of Directors. Dr. Kwon is a highly accomplished corporate executive in the life sciences and biotechnology space. He brings over a decade of expertise in strategic advising, corporate finance and business development transactions to ADMA's Board. "Young is a recognized leader in the healthcare sector and his deep strategic and financial experience
4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)
4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)
4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)
Raymond James resumed coverage of ADMA Biologics with a rating of Strong Buy and set a new price target of $5.00
Mizuho initiated coverage of ADMA Biologics with a rating of Buy and set a new price target of $5.00
Raymond James upgraded ADMA Biologics from Outperform to Strong Buy and set a new price target of $5.00
3Q 2024 Total Revenue of $119.8 Million, a 78% Increase Y-o-Y 3Q 2024 GAAP Net Income of $35.9 Million, a 1,300% Increase Y-o-Y 3Q 2024 Adjusted EBITDA(1) of $45.4 Million, a 256% Increase Y-o-Y KPMG LLP Engaged as New Independent Registered Public Accounting Firm FY 2024 and 2025 Total Revenue Guidance Increased to More Than $415 Million and $465 Million, Respectively FY 2024 and 2025 GAAP Net Income Guidance Increased to More Than $120 Million and $165 Million, Respectively FY 2024 and 2025 Adjusted EBITDA Guidance Increased to More than $160 Million and $215 Million, Respectively Conference Call Scheduled for Today at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON,
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 29, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report third quarter 2024 financial results on November 7, 2024, after the U.S. financial markets close. ADMA's management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates. To access the conference call, please dial (888) 596-4144 and refer to conference ID 2959956. It is recommended that you join approximately 10
RAMSEY, N.J. and BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced it will join the S&P SmallCap 600 index, effective prior to the open of trading on Monday, September 23, 2024. The S&P SmallCap 600 seeks to measure the small-cap segment of the U.S. equity market. "ADMA's inclusion in the S&P SmallCap 600 index is a significant milestone for our company," Adam Grossman, President and Chief Executive Officer of ADMA. "We expect this inclusion will increase our visibility within the investment communit
SC 13G/A - ADMA BIOLOGICS, INC. (0001368514) (Subject)
SC 13G - ADMA BIOLOGICS, INC. (0001368514) (Subject)
SC 13G - ADMA BIOLOGICS, INC. (0001368514) (Subject)